- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | OnKure Therapeutics GAAP EPS of -$1.09 | 1 | Seeking Alpha | ||
| 06.11. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update | 27 | GlobeNewswire (Europe) | -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients... ► Artikel lesen | |
| 06.11. | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.08. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.08. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.06. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.05. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 210 | GlobeNewswire (Europe) | -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's... ► Artikel lesen | |
| 10.03. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 317 | GlobeNewswire (Europe) | - PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024... ► Artikel lesen | |
| 10.12.24 | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | 308 | GlobeNewswire (Europe) | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,985 | +0,05 % | Millionen-Exit: Pfizer schmeißt alle BioNTech-Anteile raus - Aktie bricht ein | © Foto: Boris Roessler - dpaEin Blocktrade über mehr als 500 Millionen US-Dollar schickt BioNTech auf Talfahrt. Pfizer verkauft seine letzten Anteile - die operative Zusammenarbeit soll laut BioNTech... ► Artikel lesen | |
| SANOFI | 87,87 | 0,00 % | Milliardenmarkt im Visier: Formycon-Aktie hebt ab: Neuer Hoffnungsträger soll Sanofi-Blockbuster angreifen | © Foto: SOPA Images - Sipa USAMitten im anhaltenden Kurstief sendet Formycon ein kräftiges Lebenszeichen: Das Biotech-Unternehmen aus Bayern hat bei der Entwicklung seines neuen Biosimilar-Kandidaten... ► Artikel lesen | |
| INNOCAN PHARMA | 9,400 | -3,09 % | InnoCan Pharma: Big News noch vor dem Nasdaq-IPO? | ||
| ASSEMBLY BIOSCIENCES | 30,900 | -0,32 % | Assembly Biosciences +367%: Showdown zum Jahresende? | Es ist eine Kursrallye aus dem Bilderbuch: Die Aktie von Assembly Biosciences läuft seit Monaten auf Hochtouren, markierte bei 36,22 US$ gestern ein neues Langzeithoch. Der jüngste Quartalsbericht zeigt:... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 50,000 | -2,91 % | NEKTAR THERAPEUTICS - S-8, Securities to be offered to employees in employee benefit plans | ||
| JAGUAR HEALTH | 1,630 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue | Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion... ► Artikel lesen | |
| ROYALTY PHARMA | 34,010 | -0,18 % | Dividendenbekanntmachungen (14.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,73 USD 0,6273 EUR AGCO CORPORATION US0010841023 0,29 USD 0,2492 EUR ALBEMARLE CORPORATION PREF A US0126532003 0... ► Artikel lesen | |
| UNITED THERAPEUTICS | 416,20 | +1,14 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 56,22 | -0,78 % | BridgeBio Pharma, Inc.: Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations | - Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated:59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 10,400 | 0,00 % | Corbus Pharmaceuticals Holdings, Inc. - 10-Q, Quarterly Report | ||
| SOLIGENIX | 1,380 | 0,00 % | SOLIGENIX, INC. - 8-K, Current Report | ||
| KALA BIO | 0,565 | -5,04 % | KALA BIO, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| ACLARIS THERAPEUTICS | 2,131 | -0,88 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress | - Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:... ► Artikel lesen | |
| NEUROGENE | 19,120 | 0,00 % | Cantor Fitzgerald bestätigt Taysha-Rating nach Daten von Konkurrent Neurogene | ||
| VYNE THERAPEUTICS | 0,382 | 0,00 % | VYNE Therapeutics Inc.: VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo | Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from... ► Artikel lesen |
Das Unternehmen ONKURE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 2,940 Euro und damit -7,26 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.